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Cardiovascular disease is the leading cause of death in the United States (l).
Although the death rate from cardiovascular disease has declined slightly over the last
two decades, the incredible economic and physical burden of survived cardiova cular
events, and the risk for developing these conditions, continue to rise (2).
The burden of cardiovascular disease is the major public health problem, costing
Americans an estimated $326.6 billion in 2000 (2). Though most deaths from coronary
heart disease (CHD) occur in those over 65, over 59 million Americans have at least one
form of cardiovascular disease, including stroke, hypertension, complication from
rheumatic fever, and congenital heart disease (2). From age 45 to 64, one in nine women
and one in six men have some form of heart disease. After age 65, tho e numbers take on
a dramatic change, with one in eight men and one in three women being afflicted (2).
Mortality rates from all forms of CHD increase with age in all races, with African
Americans having the highest rate. However, this rate is only about 5% higher than
Whites (2). American Indians, Asians, and Hispanics follow in decreasing numbers,
respectively (2).
A great achievement in the fight against CHD was the identification of its risk
factors. Only after these findings was the power of prevention, not just treatment,
realized. In all population clinical and pathologic studies, high serum cholesterol level
were found to be at the forefront of risks associated with CHD, with other factors such a
smoking, obesity, and physical activity following close behind (1).
Any patient diagnosed with hypercholesterolemia is first placed on a cholesterol-
lowering diet. The American Heart Association recommends the Step I and II di ts,
which reduce dietary intake of cholesterol, fat, and saturated fat (1). The Step I and II
diets are designed to reduce low-density lipoprotein- (LDL-) cholesterol by about 8 and
15%, respectively (3). If no successful lowering of cholesterol is observed, the patient is
usually prescribed a cholesterol-lowering drug (I). Until recently, these were the only
available alternatives for those with hypercholesterolemia.
There is increasing evidence that vegetable proteins may provide a new alternative
in the prevention and lowering of elevated cholesterol levels (4). Recently, the Food and
Drug Administration approved the use of soy protein in lowering cholest rol (5).
Vegetable proteins, specifically soy proteins, reduce plasma cholesterol, esp cially when
cholesterol is elevated by dietary sources (4). The first study to show a ignificant
decrease in chol.esterol by soy protein was conducted in 1967 (4). Though there were
only six hypercholesterolemic subjects, results showed a mean decrease in cholesterol
from 7.6 mmol/L to 5 mmol/L after only 4 weeks on a diet in which the only source of
protein was textured soy protein.
This study was seemingly ignored for almost ten years. In 1977, Sirtori et al.
began a series of clinical trials with soy protein (4). An 8-week study of 127 outpatients
on a low-lipid, high polyunsaturated to saturated fat ratio diet resulted in a mean
2
reduction of cholesterol by about 23% in the 67 men and about 25% in the 60 omen (4).
Many similar studies have been conducted yielding similar results.
However, there have been several referenced studies examining soy that have not
produced positive results (6-7). In these studies, failure may have been due to patients
with very mild hypercholesterolemia, low protein content in the diet, pati nts with
hypertriglyceridemia, or any combinations of these factors (4). Other po sible
explanations include failure to follow diets, or patients who were already on some kind of
drug therapy (4).
Today, the consensus is that, despite any "negative" findings, soy protein-based
diets are effective in lowering serum cholesterol concentrations. The question then arises
as to the properties of soy that are responsible for its hypocholesterolemic effects. Initial
studies were conducted under the hypothesis that cholesterol absorption/elimination and
steroid excretion were possible mechanisms (8). Though there were reductions in total
and LOL-cholesterol in these studies, no difference in fecal steroid excretion (neutral
steroid or bile acid) could be found (8).
It was not until 1989 that the attention turned to LDL-receptor activity as another
likely explanation for the hypocholesterolemic effects of soy. When additional
cholesterol was given, textured soy protein intake stimulated clearance, most likely due to
increased LOL-receptor activity (9). Various studies, from ]989 to the present have
strengthened this hypothesis (1 0-11 ).
A possible mechanism in the hypocholesterolemic effect of soy centers on its
content of isoflavones. Isoflavones are estrogen-like compounds found in soy protein.
Estrogen has been shown to reduce or prevent the occurrence of CHD in women (12), by
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improving lipid and lipoprotein metabolism (13). Though much Ie potent than
estrogen isoflavones have the ability to interact with both known types of estrogen
receptors in humans (8).
Other theories behind the hypocholesterolemic effect of soy protein center on its
amino acid content, specifically the ratio of arginine to lysine, as well a the presence of
saponins and trypsin inhibitors (8, 14).
Also, the ability of soy to reduce cholesterol has prompted a recent focu on how
soy alters serum levels of lipoprotein(a) (15). One recent study found that oy protein
may increase lipoprotein(a) (I5).
In order to understand soy's benefits to cardiovascular health, we must
conclusively identify its effects on blood lipids and markers for cardiovascular health.
Currently, there is minimal data available regarding the effects of soy consumption in
mixed populations of normo- and mildly hypercholesterolemic men and women. Thi
study was initiated to examine the effects of 40 grams (g) soy protein daily for three
months on blood lipids and markers for coronary heart disease. The hypothesis of this
study is that soy protein consumption by humans reduces the risk of coronary heart
disease by improving serum lipid profiles and body composition. To te t our hypothesis,
we have two specific aims as follows:
Specific Aim 1: To determine if 40 g of soy protein daily for three months lowers
total and LDL-cholesterol, and increases HDL-cholesterol.
Specific Aim 2: To determine if 40 g of soy protein daily for three months lowers
Jipoprotein(a) concentration.
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Specific Aim 3: To detennine if 40 g of soy protein daily for three month affect




Incidence of Coronary Heart Disease in Humans
According to the American Heart Association (AHA), the number of death from
coronary heart disease has been on the rise as the percentage of people over the age of 65
has increased (2). This recent finding conflicts with expectations, especially since the
mortality rate from CHD was on the decline over the last decade (16). The discrepancy in
thinking seems to he due to the update of the U.S. population projection. As part of the
AHA's 1999 Heart and Stroke Statistical Update, the U.S. population projection for 2000
consists of many more older people than the last figure, calculated in 1940 (2).
Cardiovascular disease (CVD) is the leading cause of death in American men and women
(17). It causes 1.6 times as many deaths as cancer in men, and twice as many deaths as
cancer in women (17). Of the 59.7 million Americans who have some form of
cardiovascular disease, 12.2 million have coronary heart disease (17). In 1997, CVD
claimed the lives of 953,110 Americans, which accounts for 41.2 percent of all death,
and CHD was responsible for half of all CVD deaths (17). From 1900 to 1965, deaths
from CHD have risen from almost 0 to over 700,000 and have not fallen below that mark
to date (17).
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The identification of risk factors for CHD has made the goal of prevention e m
much more attainable. However, the ~remendous effort put forth to inform the public
about modifiable risk factors has been surprisingly ineffective. It appears that people are
resistant to changing old habits in ways that could seriously reduce their ri k for CHD (I).
Risk Factors for Coronary Heart Disease
Obesity
The relationship between obesity and CHD has long been established (18). The
definition of obesity varies because of the difference in criteria used in its assessment.
One classification of obesity is based on the body mass index (BMI) (19). Weight i
measured in kilograms and divided by height measured in meters squared (19). Low risk
of health complications is associated with a BMI of ~ 25-30 (20). A BMI of 30-35 is
correlated with a moderate risk of health complications (20). A BMI of 35-40 or greater
is correlated with a high risk of health complications (20).
According to the Center for Disease Control, 105.7 million Americans age 20 and
older are considered overweight (using a BMI of 25 or higher), and 43.] million are
considered obese (using a BMI of 30 or higher) (17).
As important as the amount of fat weight in assessing CHD risk, the distribution
of fat plays a key role as well. Studies have shown that upper body fat, particularly
abdominal fat, has been linked to a greater increase in risk for CHD than lower body fat
(21). Upper body fat, also termed android fat, is particularly common in men. This may
also explain the increased risk for CHD in men than women of similar age (2]).
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Physical activity
Lack of physical activity is a risk factor for development of CHD (l). About 25%
of all Americans age 18 or older have no leisure-time physical activity, and at lea t 60%
of adults do not achieve the recommended 30 minutes of vigorous physical activity at
least 3-4 days per week (17). Benefits of physical activity in the prevention of CHD
include, but are not limited to: improved vascular integrity, decreased resting blood
pressure, decreased resting heart rate, increased heart efficiency, as well as a significant
improvement of blood lipid profiles (22). Exercise has been shown to signiticantly
decrease total cholesterol, LDL-cholesterol and triglycerides, and increase HDL-
cholesterol (23-24).
Smoking
There are more preventable deaths from cardiovascular disease caused by
smoking than any other modifiable risk factor (25). Smoking causes about 1 in 5 deaths
from cardiovascular disease (17). The main cause of death related to moking i
myocardial infarction. Smoking accelerates the rate of atherosclerosis and is implicated
in cardiac complications such as hypercoagulability, increased cardiac work, reduced
oxygen transport, catecholamine liberation, and vasoconstriction (26).
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Hyperlipidemia
About 99.5 million Americans have a total blood cholesterol level :::: 200 mg/dL,
which is considered borderline-high (17). Nearly 40 million Americans have a total
blood cholesterol:::: 240 mg/dL, which is considered high (17). These numbers indicate
the extent to which Americans are battling high blood lipids.
Triglycerides, non-esterified fatty acids, phospholipids, and cholesterol are the
major lipids found in the blood. Cholesterol and phospholipids make up hormones and
membranes of cells. Because triglycerides and non-esterified fatty acids are in oluble in
water, their transport in the aqueous environment of the blood is very difficult. In order
to travel in the blood, they must be bound to the abundant serum protein, albumin, or
inside the core of special transport proteins called lipoproteins. Transport with albumin is
relatively inefficient, therefore the majority of lipids are transported via lipoproteins.
Lipoproteins are composed of a triglyceride and cholesterol core surrounded by a
hydrophilic layer of phospholipids and cholesterol, as well as apolipoproteins, which are
dispersed throughout the lipoprotein. Apolipoproteins can function in structure
stabilization, receptor recognition, enzyme activation, or any combination of these.
The four primary classes of lipoprotei.ns, in order of lowest to highest density, include
chylomicrons, very low density lipoprotein (VLDL), low density lipoprotein (LDL), and
high density lipoprotein (HDL). Chylomicrons make up the major portion of lipoprotein
from dietary fat and are usually not present in the blood stream during the fasting state.
VLDL's presence in the blood is very short lived, as it is quickly converted to LDL.
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Low-density lipoprotein transports about 60% of the cholesterol found in the blood.
Its main function is to carry cholesterol to tissues where it is used in making cell
membranes and hormones. LDL binds to receptors in cell walls, and is then taken in by
the cell and degraded. This process is especially important in the endothelium of the
vascular system, where the process of atherosclerosis, and ultimately coronary heart
disease originates.
Atherosclerosis is a disease of the vascular endothelium in which lipid material
accumulates in the vessel walls, eventually causing swelling, or even damage to the
endothelium, which accelerates th~ collection of lipids and proteins. This deposited lipid
combined with clotting factors and proteins is known as plaque. An excess of LDL in the
endothelium promotes the formation of plaques, which can expand inner vessel walls,
and ultimately cause blockage (27).
High-d~nsity lipoprotein, the other major carrier of cholesterol, oppo e LDL by
removing cholesterol from the artery wall, and by preventing the oxidation of lipids in
LDL. The role of HDL in atherosclerosis is significant, as it can prevent the formation of
plaques by removing deposited cholesterol in the vascular endothelium (27).
A lipoprotein often overlooked when considering risk factors for CHD is
lipoprotein(a) (Lp(a». High lipoprotein(a) levels are correlated with premature
myocardial infarctions. Lp(a) may contribute to clot formation through several
mechanisms including inhibited fibrinolysis, increased oxidation of LDL-cholesterol, and
increased deposition of cholesterol in arterial walls (28). Lp(a) consists of low-density




From our understanding of cholesterol, it is clear that reducing LDL-cholesterol
can prevent fonnation and progression of plaques that may block vessels. Many of
today's lipid- lowering drugs are engineered to reduce LOL-cholesterol levels. However,
these drugs must be taken continuously in order to achieve continued result (29).
One of today's most widely used lipid-lowering drugs is the classification known
as hydroxymethyglutaryl coenzyme A (HMG-CoA) reductase inhibitors ("statins"). Such
drugs include: fluvastatin (Lescol™), pravastatin (PravachoI™), simvastatin (Zocor™),
Lovastatin (Mevacor™), atorvastatin (Lipitor™), and cerivastatin (BaycoI™). As the
name implies, these drugs work by inhibiting HMG-CoA reductase, the rate-limiting
enzyme that catalyzes the conversion of HMG-CoA to mevalonate, in the synthesis of
cholesterol. It has been reported that these drugs are most effective in lowering LOL-
cholesterol and triglycerides, and they may increase HOL level as well (29).
Another classification of lipid-lowering drugs is known as fibric acid derivatives
("fibrates"). This class of drugs includes gemfibrozil (Lopid™), fenofibrate (Triclor™),
clofibrate (Atromid-S™), and bezafibrate (BezalipTM). Fibrates are most often effective
in lowering triglycerides, but may also decrease LDL-cholesterol and increase HDL-
cholesterol, by involving the activation of peroxisome proliferator-activated receptor-
alpha-l in the liver, thereby improving transport rates of several lipoproteins (30, 31, 32).
Niacin (nicotinic acid) is used to decrease triglycerides, LDL-cholesterol, and
lipoprotein(a), but most effectively increases HDL-cholesterol (33, 34). The use of niacin
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to improve lipid profiles has been limited due to the side effects exp rienced from th
high amounts and inconvenient dosing schedules required (7, 33).
Bile-acid binding resins, cholestyramine (Questran) and colestipol (Colestid) ar
most effective in lowering LDL-cbolesterol in people without hypertriglyc rid mia (35).
They work by up-regulating LDL-receptor, thereby decreasing intrahepatic chole terol
through interruption of enterohepatic circulation of cholesterol-rich bile acids (36). The
most common complaints from users of resins include GI upset and constipation (29).
Resins were among the very first drugs developed for hyperlipidemia, but their use has
diminished over time with the development of other more effective drugs with fewer side
effects.
The Hypocholesterolemic Property of Soy
Recently the Food and Drug Administration (FDA) approved soy as a food source
that can lower cholesterol and therefore lowers the risk of CHD. The FDA' approval i
based on numerous animal and clinical studies that have shown the efficacy of soy in
lowering cholesterol. The hypocholesterolemic effects of soy protein have been
extensively studied in men, premenopausal women, postmenopausal women, and variou
animal models (8, 9, 11, 37-38). However, its cholesterol lowering effect in mixed
populations have not been studied. Postmenopausal women, in particular, can benefit
from consumption of soy products since their risk for cardiovascular disea e nearly
doubles as they enter menopause (5, 39).
Isoflavones are constituents of soy that has been extensively investigated.
Isoflavones belong to a class of phytochemicals called phytoestrogens, named for their
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similarity in function to estrogen. Genistein, the most predominate isoflavon , has been
shown in vitro and in vivo to have an estrogenic effect about 1 x 10-4 that of e tradiol
(12). Isoflavones are readily converted by intestinal bacteria into equol, which is rapidly
absorbed in the gut, conjugated in the liver, and excreted in the urine. Elevated urinary
isoflavone levels (as much as 1,000-fold) have been reported in humans following soy
consumption (21).
Soy protein also contains several trypsin inhibitors, which work by stimulating the
secretion of cholecystokinin (40). Cholecystokinin stimulates contraction of the gall
bladder and bile acid secretion, which binds cholesterol in the intestine for excretion. Soy
protein contains considerable amounts of the Bowman-Birk inhibitor, a trypsin inhibitor
found in some grains and beans, which may partially explain the hypocholesterolemic
effect of soy protein. However, studies conducted with soy protein, casein, and varying
amounts of added trypsin inhibitor suggest that its role is negligible (40).
Vegetable proteins, specifically soy protein, contain compounds known as
saponins (8). Saponins are complex structures consisting of carbohydrate moities
attached to an aglycon, a steroidal molecule. It has been suggested by animal studies that
saponins decrease cholesterol by increasing bile acid excretion (41). However, when
saponins are added to soy protein, no effects are observed (42), giving the idea that
saponins are not responsible for the cholesterol-lowering effect of soy protein.
Also present in soy protein are phytates, or phytic acid, which chelate calcium,
]fon, magnesium, and zinc, thus decreasing thl:ir absorption. Diets with high zinc to
copper ratios are associated with hypercholesterolemia (8). Animal studies have shown
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that addition of phytates to the diet lowered serum total cholesterol (43). Therefore it is
theorized that by improving the zinc to copper ratio, soy protein lowers cholesterol.
The amino acid content of soy protein has also been considered as a basi for its
hypocholesterolemic effect. Animal studies have reported that arginine decrea e blood
cholesterol levels, while lysine increases blood cholesterol levels (44). Soy protein ha a
more suitable ratio of arginine to lysine than other proteins, such as casein (8). One
animal study showed that adding lysine to soy protein caused an increase in total
cholesterol by about 50% (14).
Other animal studies have reported that when soy protein is exposed to pepsin,
two different fractions, high-molecular-weight fraction (HMF), and lower-molecular-
weight fraction (LMF), are formed (45). When HMF was fed to hypercholesterolemic
women, steroid excretion increased and cholesterol levels decreased (46).
The exact mechanism, or mechanisms, underlying soy protein's abil ity to low r
cholesterol is not completely understood. There are many nutritive and non-nutritive
constituents of soy protein that have been, and continue to be investigated. It is most




RESEARCH DESIGN AND METHOD
Subject Characteristics
Men and women with diverse ethnic backgrounds, who live in metropolitan and
rural areas within reasonably commutable distances, were recruited for this study from
Oklahoma State University faculty and staff, health-care clinics, independent living
facilities, churches, and through advertisements at large in Stillwater, Oklahoma, and the
surrounding area. A total of 135 mobile individuals (65 men and 70 women), ranging in
age from 27 to 87 years were included in the study. Subjects were pre-sere ned via a
phone interview, which included a short medical history questionnaire to identify
qualified potential participants. Subjects were excluded if they had rheumatoid arthritis,
joint pain due to injury, cancer or a history of cancer, insulin dependent diabetes mellitu ,
kidney disease, gastrointestinal or chronic digestive disorders, and allergy to milk, eggs,
or soy. There were no special selection criteria in regard to cholesterol levels. A total of
ninety subjects (44 men and 46 women) completed the study.
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Study Overview
The study was a double-blind design. Eligible men and women were randomly
assigned to consume 40 g of protein per day in the form of a powdered supplement
containing either soy protein or casein (control). Of the 135 initial study participants, 64
consumed soy and 71 consumed casein. It was made clear to the study participants that
they had an equal chance of being placed on either the soy or the casein regimen. The
treatment period was three months. Regimens were provided to the subjects monthly for
daily consumption of two packets containing a powdered drink mix, donated by Protein
Technologies International (St. Louis, MO). Both regimens supplied equal amounts of
protein (40 g/day), carbohydrate (18 g/day), fat (0 g/day), and total calories (240
kcallday). The rationale for choosing the soy dose (40 g/day) was based on the effective
amount previously used in clinical studies (11). Compliance with the study protocol was
monitored via the following means: 1) subjects were provided with a monthly calendar
for recording consumption of the contents of the provided packets on a daily ba is; 2)
subjects returned any unconsumed packets to the investigators on their monthly visits,
unused supplies were counted and recorded; and 3) body weight was monitored monthly
to ensure the treatment regimens were not promoting excess caloric intake. Subjects were
given access to an RD/LD for advice on how to incorporate the supplement into their
diets. A total of ninety subjects (44 men and 46 women) completed the study with 45
subjects on each of the two treatments.
Subjects met with the investigators for a total of five visits. Visit 1 included a
verbal and a written explanation of the project, signing a consent form, a detailed medical
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history questionnaire to confi.rm prescreening findings and to insure that ubject did not
have any conditions violating the inclusion/exclusion criteria. Subjects were scheduled to
come back to the study site and instructed regarding blood and urine collection for their
next visit. Visit 2 occurred between the hours of 8-10 a.m. for the collection of ov r-
night fasted blood samples (20 ml) of venous blood drawn by a regist red and licen d
nurse), a 24-hour urine specimen collected during the day prior to this visit, and
anthropometric data. Anthropometric measurements included: height, weight, and waist
to hip ratio. Participants were given their food supplies at this visit. Visits 3 and 4 were
monthly visits for the purposes of replenishing the subject's food supply, monitoring
intake of the supplies as well as body weight. The final visit, visit 5, occurred three
months from initiation of the study, and included all measures and assessments performed
on Visit 2.
Subject Confidentiality
Upon entrance into the study, each subject was assigned an identification number.
This number was used for tracking the subject's records throughout the study. The
principal investigator kept confidential data such as medical history, nutrition
questionnaire and assigned numbers in a secured cabinet with restricted access.
Thereafter, the samples from each study participant carried a number with no personal
information available to the laboratory or data entry personnel.
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Blood Collection and Serum Analyses
Fasting venous blood for plasma and serum analyses were collected at a
designated time from each subject in Vacutainer (Franklin Lakes, NJ) tubes with
appropriate anticoagulants or without anticoagulants at baseline and at the end of the
study. Serum and plasma were separated from the blood (centrifuged at 1500 x g for 20
minutes) within 2 hours of collection and immediately aliquoted into small volumes and
stored at -80aC until required for analysis. In this study, we measured serum total
cholesterol, HDL-cholesterol, triglycerides, and lipoprotein(a). All the measurement
were reported in Standard International (SI) Units.
Serum triglycerides (TG) and total-cholesterol (TC) were determined
enzymatically using kits from Roche Diagnostic Systems (Somerville, NJ). The method
for total cholesterol is based on the procedure described by Allain et al (47). Cholest rol
is released enzymatically from its esters by cholesterol esterase. Total free cholest rol is
oxidized by cholesterol oxidase producing hydrogen peroxide. Hydrogen peroxide, when
combined with 4-aminoantipyrine and phenol, forms a quinoneimine dye that absorbs at
500 run. The absorbance is directly proportional to the cholesterol concentration in the
sample.
In the assessment of triglycerides, they are hydrolyzed by lipoprotein lipase to
glycerol and fatty acids. Glycerol then reacts with adenosine triphosphate (ATP) and
oxygen to produce hydrogen peroxide. The hydrogen peroxide reacts with 4-chlorphenoJ
and 4-aminophenazone, and forms a quinoneimine dye that absorbs at 500 nm. The
absorbance is directly proportional to the tryglyceride concentration in the sample.
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Serum HOL-cholesterol was determined by a direct method (Unimate HDL
Direct, Roche Diagnostic Systems, Somerville, NJ) utilizing synthetic polymers,
polyanions and detergent. These compounds solubilize cholesterol from VLDL, LDL and
chylomicrons but not HDL. The cholesterol in HOL is then determined enzymatically
using the method described by Allain et al (48). LDL cholesterol was calculated u ing
the Friedewald equation: (48).
LDL-C = (Total-C) - (HDL-C) - (TG/5)
Lipoprotein(a) was determined by an immunoprecipitation technique (DiaSorin,
Stillwater, MN). The sample (antigen) is reacted with an antibody producing turbidity.
The amount of turbidity is directly proportional to sample concentration and is measured
at a wavelength of 340 nm.
Each of these tests were performed on a Cobas-Fara II Clinical Analyzer
(Montclair, NJ) following the manufacturer's instruction and u ing commercially
available calibrators and quality control samples.
Anthropometric Measurements
Height, weight, and waist-to-hip ratio were collected at baseline. Waist-to-hip
ratio was measured during the final visit. Weight was monitored during each monthly
follow-up visit. If weight gain was apparent, counseling was available to make
adjustments in the diet to prevent further gain. Instructions were also provided for
inclusion of the supplement into the diet. The protocol for assessing anthropometric
measurements was adopted from the NHANES III survey (49).
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Body weight was measured on a medical scale (H alth-O-Meter Continental
Scale Corp., Chicago, IL) and subjects dressed in light clothing and without shoe or
jewelry. The height was taken on an Acustat Genetech Stadiometer (San Francisco, CA).
Subjects were asked to take a deep breath, stand with their heels together and touching
the wall, and their shoulders and head touching the back of the stadiometer. Height were
measured to the nearest O.I-inch.
Circumferences were measured with measuring tape while subjects were wearing
light clothing, were relaxed, were standing erect, and had their arms at their sides and feet
together. Waist circumference was measured midway between the lower rib and iliac
crest whereas hip circumference was measured at the outermost points of the greater
trochanters (50). The value obtained was the ratio of the waist circumference to the hip
circumference.
Data Management and Statistical Analyses
A graduate student trained for permanent storage of data compiled the data from
subjects on a weekly basis and entered it into the central database filing system. The
laboratory-generated raw data and printouts were recorded/kept in a secured storage area.
All of the original data were stored in a locked cabinet with restricted acce s.
Descriptive statistics were calculated for all variables and included means and
standard deviations. The data were analyzed using PC SAS version 6.12 (SAS Inst.,
Carry, NC). The primary outcome variables were serum lipid parameters and
anthropometric parmeters. Treatment (soy vs. casein) effects were assessed using
20






Subjects participating in this study included one hundred thirty-five healthy men
and women with a mean (±SD) age of 57.6 ± 1.1 years. Subject dropouts included a total
of forty-five over the entire course of the study, who were also excluded from statistical
analyses. Reasons for discontinuing included taste aversion, gastrointestinal disturbance,
inconvenience of powdered-protein consumption, or starting a new drug therapy that
could affect the outcome of the study.
Anthropometric Measurements in All Participants
Consumption of 40 g soy protein or casein daily for a three-month period did not
significantly increase body weight. In contrast, subjects on soy protein had somewhat
(-2.44 lbs) lower final body weights. There were no observed significant differences in
anthropometric measurements between the treatment groups (Table I).
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Serum Lipid Levels in All Participants
The changes in the serum levels of cholesterol triglycerides and Lp(a) before and
after both treatments are reported in Table II. Soy protein did not lower erum total- and
LDL-cholesterol or Lp(a) in comparison with casein. Additionally as expected, soy
regimen somewhat (p<O.l) increased serum HDL cholesterol concentrations in
comparison with casein.
Serum Lipid Data for All Participants with Total Cholesterol ~200 mg/dl
Soy protein also did not lower serum total cholesterol in comparison with casein
after subjects with total cholesterol measurements <200 mg/dl were eliminated from the
data set.
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Table I. Anthropometric Data for All Participants
Effect Of Effect Of




Parameters Baseline Final Baseline Final p-value p-value






(lbs) 209.70 ± 62.79 206.26 ± 64.6\ \97.46 ± 40.83 \99.11 ± 41.87 <0.41 <0.22
n=43 n=43
Height (in) 67.93 ± 0.45 67.79 ± 0.42---- ---- ---- ----
n=43 n=43
Body Fat %
36.1 ± 7.20 35.10±9.87 35.87 ± 7.48 35.01 ± 7.05 <0.56 <0.85
n=34 n=34
8MI 31.64 ± 8.4) 31.19±8.80 30.48 ± 6.68 30.75 ± 6.90 <0.4\ <0.25
n=42 n=40
Waist (in) 40.32 ± 6.88 40.88 ± 6.94 39.17±5.67 39.95 ± 5.95 <0.26 <0.68
n=43 n=43
Hip (in) 44.98 ± 7.\3 44.99 ± 7.50 43.87 ± 5.09 43.86 ± 5.6 <0.74 <0.94
n=43 n=43
WaistHip Ratio
(in) 0.89 ± 0.06 0.9\ ± 0.07 0.89 ± 0.07 0.91 ± 0.06 <0.24 <0.83
n=43 n=43




Table II. Serum Lipid Data for all Participants
Soy Protein Casein Effect of Effect of
Treatment*Gender Treatment
Serum
Parameters Baseline Final Baseline Final p-value p-value
Total Cholesterol
Cmg/dl) 221.15 ± 41.09 221.50 ± 37.21 229.20 ± 46.28 229.70 ± 45.98 <0.57 <0.98
n=44 n=44
HDL-cholesterol
(mg/dl) 56.16 ± 20.75 58.02 ± 16.42 58.73 ± 18.41 57.43 ± 2.56 <0.90 <0.10
n=44 n=44
Triglyceride




\23.47 ± 35.99 123.09±36.15 136.60 ± 38.01 \32.10 ± 33.89 <0.60 <0.31
n=44 n=44
Lipoprotein(a)
(mg/dl) 25.55 ± 26.81 29.93 ± 27.68 33.65 ± 32.95 36.01 ± 35.84 <0.6\ <0.35
n=42 n=38
Values presented are mean ± SO.
V)
N
Table III. Serum Lipid Data for all Participants with Total Cholesterol < 200 mg/dl
Soy Protein Casein Effect of Effect of
Treatment*Gender Treatment
Serum
Parameters Baseline Final Baseline Final p-value p-value
Total Cholesterol
for All Participants 246.86 ± 34.14 237.32 ± 29.93 247.79 ± 33.43 250.69 ± 39.36 <0.50 <0.32
(mg/dl) 0:::;28 0=32
Total Cholesterol
for All Men 248.47 ± 28.19 230.57 ± 21.81 243.67 ± 32.54 246.36 ± 45.17 ---- ----
(mg/dl) n:::;14 n=11
Total Cholesterol
for All Women 245.58 ± 31.79 244.07 ± 42.97 250.34 ± 34.28 252.95 ± 36.95 ---- ----
(mg/d)) n=14 0=21






The present study was designed to evaluate the cholesterol-lowering properties of
soy protein in comparison with casein, as a part of an unmodified diet. Many clinical
trials have demonstrated the hypocholesterolemic effects of soy protein in subjects with
elevated serum cholesterol (6-8, 10). The results of this study neither confirm nor reject
the potential benefits of soy consumption on lipid profiles in humans. The findings of this
study indicate that consumption of soy protein in the amount of 40 g per day has little
effect on total-, HDL-, and LDL-cholesterol concentrations in norrnolipidemic a well a
mildly hypercholesterolemic men or women. For the present study, however, it should be
noted that subjects were not recruited on the basis of baseline cholesterol value. In fact,
the study participants were only mildly hypercholesterolemic, with average means of
baseline total cholesterol ranging from 222 to 224 mg/dl, respectively for soy and ca ein
regimens. Also, as part of the original study protocol, study participants were not
required to modify their dietary intake, as has been the case in many clinical trials
examining the hypocholesterolemic effects of soy protein (51-52).
One interesting effect of soy protein was its ability to lower serum triglyceride
levels in comparison to casein. The lowering effect is accentuated by the large increase in
triglyceride levels in those on the casein regimen. One explanation for this effect may be
27
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the lower baseline triglyceride level in those on the casein regimen esp ciaJly if study
participants were not truly fasting for their fmal blood draw.
It is also difficult to explain the lack of effect of soy protein on serum cholesterol
especially given the majority of studies demonstrating a cholesterol-lowering effect of oy
protein, and the recent FDA approval of the use of soy protein to lower cholesterol. One
possible explanation could be the near normal baseline cholesterol levels of the
participants. It has been clearly established in several studies that the reduction of
cholesterol with soy protein was inversely related to the baseline level of cholesterolemia
(4). However, when the 60 subjects with total cholesterol levels below 200 mg/dl were
excluded from analyses, there was no significant lowering of total cholesterol observed.
Many studies demonstrating the hypocholesterolemic effect of soy protein required
subjects to totally or partially replace animal protein with soy protein (11, 52), or to
follow a conventional low-fat (39), or NCEP Step I diet (21). No dietary modification
other than consumption of the powdered supplement were required in this study.
Conclusions
The results of this l2-week study suggest that soy protein exhibits little effect on
anthropometric parameters associated with coronary heart disease. Furthermore, soy
protein may also be of little benefit in lowering blood lipids of normolipidemic men and
women. However, it should be noted that soy protein exhihited much more favorable
effects on blood lipid profiles after 24 weeks on a soy protein regimen (11). It should be
also be noted that soy protein exhibited much more favorable effects on anthropometric
28
and lipid parameters in this study when using a paired He t to compare the two
treatments' (soy protein and casein) baseline and final measurements (Appendix II).
Additional studies are needed to confirm whether the beneficial effi cts of oy
protein on blood lipid profiles and body composition found in other studies ar due to the
addition of soy protein, or are merely due to dietary modifications. It may be the case that
soy protein has a synergistic effect on blood lipids when combined with a low-fat diet.
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ANTHROPOMETRIC AND SERUM LIPID DATA ASSESSED USING A T-TEST
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Table I. Anthropometric Data for All Participants
SOY PROTEIN CASEIN
Physical
Parameters Baseline Final p-value Baseline Final p-value




Body Weight 211.70±6.51 206.26 ± 8.69 <0.24 195.74±6.ll 199. 11 ± 8.7 I <0.58
(lbs) 0=43 0=43
Height (in) 67.93 ± 0.45 67.79 ± 0.42
---- ---- ---- ----
0=43 0=43
Body Fat % 36.10 ± 1.04 35.10 ± 1.15 <0.01 35.87 ± 0.96 35.01 ± 1.11 <0.02
0=34 0=37
BMI 32.38 ± 0.99 31.12± 1.19 <0.30 30.20 ± 0.95 30.61 ± 1.20 <0.55
n=42 0=40
Waist (in)
40.10 ± 0.80 40.88 ± 1.00 <0.15 38.77 ± 0.75 39.95 ± 1.00 <O.O-l
0=43 0=43
Hip (in)
45.34 ± 0.81 44.99 ± 1.03 <0.97 43.46 ± 0.77 43.85 ± 1.02 <0.95
0=43 0=43
WaistHip Ratio
(in) 0.90 ± 0.01 0.91 ± 0.01 <0.06 0.89 ± 0.01 0.91 ± 0.01 <0.03
0=43 0=43




Table II. Anthropometric Data for All Men
SOY PROTEIN CASEIN
Physical
Parameters Baseline Final p-value Baseline Final p-value
Age (yrs)
55.38 ± 2.40 56.86 ± 2.18---- ---- ---- ----
n=22 n=20
Body Weight
233.74 ± 9.56 224.94 ± 12.15 P<0.09 199.82 ± 8.70 202.35 ± 12.74 P<0.70(lbs)
n=22 n=20
Height (in) 71.01 ± 0.66 69.72 ± 0.60---- ---- ---- ----
n=22 n=20
Bodyfat % 32.79 ± 1.52 31.97 ± 1.63 P<0.17 31.70::: 1.36 i 30.78 ± 1.63 P<0.08
0=17 n=17
BMI 32.80 ± 1.46 30.70 ± 1.67 P<0.11 29.23 ± 1.37 29.31 ± 1.75 P<0.69
0=22 n=18
Waist (in)
41.97± 1.18 42.85 ± 1.39 P<O.57 39.23 ± 1.07 40.65 ± 1.46 P<0.04
n=22 0=20
Hip (in) 45.90 ± 1.20 45.26 ± 1.46 P<O.92 42.76± 1.10 42.88 ± 1.50 P<0.62
n=22 n=20
Waist:Hip 0.94 ± 0.01 0.96 ± 0.01 P<0.24 0.92 ± 0.01 0.95 ± 0.02 P<O.OI
Ratio 0=22 n=20
Values presented are mean ± SD.
0-.
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Table III. Anthropometric Data for All Women
SOY PROTEIN CASEIN
Physical
Parameters Baseline Final p-value Baseline Final p-value
Age (yrs) 59.23 ± 2.18 58.69 ± 2.15---- ---- ---- ----
0=22 0=24
Body Weight 189.66 ± 8.83 187.58 ± 12.43 <0.99 191.65 ± 8.58 195.88 ± 11.88 <0.68
(lbs) 0=21 0=23
Height (in) 64.86 ± 0.61 65.87 ± 0.60---- ---- ---- ----0=21 n=23
Bodyfat % 38.81 ± 1.43 38.23 ± 1.63 <0.02 39.7\ ± 1.34 39.24 ± \.50 <0.09
0=17 n=20
8MI 31.96± 1.35 J 1.53 ± 1.71 <0.92 31.18 ± 1.33 31.92 ± 1.63 <0.66
0=20 0=22
Waist (in) 38.24 ± 1.09 38.90 ± \.42 <0.14 38.31 ± 1.06 39.24 ± \.36 <0.43
0=2\ 0=23
Hip (in) 44.79 ± 1.10 44.71 ± 1.46 <0.88 44.16 ± 1.07 44.83 ± \.40 <0.66
0=21 0=23
Waist:Hip 0.86 ± 0.01 0.87 ± 0.0\ <0.\5 0.87 ± 0.01 0.87 c:: 0.0\ <0.59
Ratio 0=21 n=23
Values presented are mean ± SO
o
-.:t
Table IV. Serum Lipid Data for All Participants
Soy Protein Casein
Serum
Parameters Baseline Final p-value Baseline Final p-value
Total Cholesterol
(mgldl) 224.\6 ± 5.45 221.84 ± 6.4\ <0.86 222.27 ± 5.\ 5 229.70 ± 6.43 <0.89
n=44 n=44
HDL-cholesterol
(mgldl) 57.03 ± 2.56 58.02 ± 2.55 <0.17 60.36 ± 2.42 57.43 ± 2.56 <0.34
n=44 0=44
Triglyceride




127.63 ± 4.83 \23.09 ± 5.39 <0.88 \26.44 ± 4.56 132.10±5.41 <0.\2
n=44 n=44
Lipoprotein(a)
(mg/dl) 25.89 ± 3.67 30.08 ± 5.33 <0.005 26.02 ± 3.43 35.13 ± 5.55 <0.\5
n=42 n=38
Values presented are mean ± SO.
.q-
Table V. Serum Lipid Data for All Men
SOY PROTEIN CASEIN
Serum
Parameters Baseline Final p-value Baseline Final p-value
Total Cholesterol
(mg/dl) 226.03 ± 8.05 220.68 ± 9.06 <0.82 207.63 ± 7.33 214.40 ± 9.50 <0.63
n==22 n=20
!
HDL-cholesterol 50.83 ± 3.78 53.55 ± 3.61 <0.46 55.26 ± 3.44 52.20 ± 3.79 <0.32
(mgldl) n=22 n=20
Triglycerides 211.34 ± 19.64 194.41 ± 24.76 <0.38 178.57± 17.88 180.65 ± 25.97 <0.11
(mgldl) n=22 n=20
LDL-cholesterol








Table VI. Serum Lipid Data for All Women
SOY PROTEIN CASEIN
Serum
Parameters Baseline Final p-value Baseline Final p-value
Total Cholesterol
222.29 ± 7.33 223.00 ± 9.06 P<0.63 236.92 ± 7.23 245.00 ± 8.68 P<0.90(rng/dl)
n=22 n=24
HDL-choIesteroI
(rng/dl) 63.23 ± 3.44 62.50 ± 3.61 P<0.23 65.47 ± 3.40 62.67 ± 3.46 P<0.74
n=22 n=24
Triglycerides
183.66 ± 17.88 212.86 ± 24.76 P<O.71 176.06 ± 17.63 221.04 ± 23.71 P<0.02(rng/dl)
11=22 n=24
LDL-cholesterol
(rng/dl) 122.33 ± 6.50 117.93 ± 7.62 P<0.80 136.23 ± 6.41 138.13 ± 7.29 P<O.06
n=22 n=24
Lipoprotein(a)
29.11 ± 4.88 39.96 ± 7.63 P<O.OO6 27.21 ± 4.88 32.79 ± 7.45 P<0.19(rng/dl)
n=21 n=20




Effects of Soy Protein Compared to Casein Using aT-Test
The previous tables contain the results of comparing the treatments' (soy protein
and casein) baseline and final measurements using a t-test. The findings of this study
according to these statistical analyses indicate that consumption of soy protein in the
amount of 40 g per day has little effect on total-, HOL-, and LDL-cholesterol, or
triglyceride levels. It is important to note that there was a trend of increasing LDL-
cholesterol among women in the casein group. However, soy protein did not exhibit
either of these effects in women.
An important effect of soy protein consumption was the significant increase
(p<0.006) in lipoprotein(a) among women. This effect was not observed in men, as
levels remained unchanged. High levels of lipoprotein(a) are now can ider d an
independent risk factor for coronary heart disease, and have been reported to be a genetic
factor that could affect a pathogenic trend in coronary heart disease. Since clinical
reviews report that lipoprotein(a) levels do not respond to dietary intervention or some
lipid-lowering drugs, it is interesting to observe this effect of soy protein. However, our
data are not the first to report this effect of soy protein on Lp(a) (15). [t is also interesting
to note that Lp(a), a complex of LOL, increased independently of LOL-cholesterollevels
among women on soy protein. This suggests that Lp(a) levels are controlled
independently of LDL-cholesterol.
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The findings of these statistical analyses suggest that soy protein may improve
body compositi0n by decreasing body fat percentage. In the soy protein group, a
decrease in body fat percentage on average was observed in both men (-0.82%) (p<0.17)
and women (-0.58%) (p<0.02). Subjects in the casein group tended to have decreased
percent body fat, however, there were also significant increases in waist-to-hip ratio
measurements in all subjects on the casein regimen. These findings suggest that soy
protein may be beneficial in reducing abdominal body fat, especially in men, whose risk
for CHD is higher than in women, particularly when considering high BMI and waist-to-
hip ratio.
Conclusions
The results of these statistical analyses suggest that soy protein exhibits a
favorable effect on % body fat and body fat distribution associated with coronary hart
disease. Furthermore, soy protein may also be of benefit in maintaining healthy blood
lipid profi.les, in spite of it increasing serum levels oflipoprotein(a) in women.
Longer study duration and dietary restrictions, such as low-fat, Step I, or tep II
diets are needed to further elucidate the role of soy in the reduction of CHD risk. If other
investigators confirm the findings of these analyses, further studies will be needed to
determine if the previously reported beneficial effects of soy protein on blood lipid
parameters and body composition are due to protein consumption alone, or the many
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